KRRO
Korro Bio, Inc. NASDAQ Listed Oct 3, 2019$12.99
+17.56%
vs $11.05
Mkt Cap $122.0M
52w Low $5.28
16.7% of range
52w High $51.36
50d MA $12.20
200d MA $17.71
P/E (TTM)
—
EV/EBITDA
—
P/B
2.4x
Debt/Equity
0.8x
ROE
-228.0%
P/FCF
-1.5x
RSI (14)
47.50
ATR (14)
$1.10
Beta
2.43
50d MA
$12.20
200d MA
$17.71
Avg Volume
168.5K
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
One Kendall Square · Cambridge, MA 02139-1562 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -1.73 | -1.69 | +2.1% | 13.34 | -2.5% | -3.4% | -6.5% | -4.9% | -2.1% | -0.2% | — |
| Mar 12, 2026 | AMC | -1.93 | -5.32 | -175.6% | 11.50 | +19.9% | +11.3% | -1.6% | -2.3% | -7.3% | -3.1% | — |
| Nov 12, 2025 | AMC | -2.61 | -1.92 | +26.4% | 31.42 | -77.8% | -79.3% | -6.6% | +1.3% | +1.1% | +3.1% | — |
| Aug 12, 2025 | AMC | -2.54 | -2.74 | -7.9% | 15.99 | +1.9% | +18.4% | +5.0% | +1.9% | -2.7% | -2.9% | — |
| May 7, 2025 | AMC | -2.60 | -2.49 | +4.2% | 13.93 | -1.8% | +10.6% | +1.0% | +2.7% | -2.7% | -9.3% | — |
| Mar 18, 2025 | AMC | -2.33 | -2.26 | +3.0% | 24.17 | +1.0% | -1.9% | -7.7% | +8.5% | +1.1% | -15.2% | — |
| Nov 12, 2024 | AMC | -2.55 | -2.26 | +11.4% | 65.14 | +1.3% | -15.6% | -9.7% | -4.3% | -2.0% | +0.0% | — |
| Aug 13, 2024 | AMC | -2.40 | -2.43 | -1.2% | 36.36 | +3.9% | +9.2% | +13.6% | -2.6% | -1.0% | -2.7% | — |
| May 14, 2024 | AMC | -2.36 | -2.44 | -3.4% | 50.05 | +1.0% | +5.4% | -2.9% | +6.6% | -0.1% | -7.0% | — |
| Mar 29, 2024 | AMC | -2.36 | -25.65 | -986.9% | — | — | — | — | — | — | — | — |
| Nov 2, 2023 | AMC | -17.73 | -15.50 | +12.6% | 14.15 | +2.5% | +6.0% | +3.2% | +59.0% | +68.2% | -0.7% | — |
| Aug 10, 2023 | AMC | -0.44 | -0.30 | +31.8% | 34.20 | +1.2% | -0.4% | -2.6% | +5.6% | -8.6% | +0.0% | — |
| May 12, 2023 | AMC | -0.39 | -0.55 | -41.0% | 18.55 | -5.7% | -5.1% | +2.3% | +10.0% | -2.8% | +0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18 | Citigroup | Initiates | Buy | $21 | $10.18 | $10.28 | +1.0% | -2.1% | -8.2% | +9.4% | +11.9% | +3.7% |
| Mar 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $11.50 | $13.79 | +19.9% | +11.3% | -1.6% | -2.3% | -7.3% | -3.1% |
| Mar 13 | Raymond James | Upgrade | Market Perform → Outperform | — | $11.50 | $13.79 | +19.9% | +11.3% | -1.6% | -2.3% | -7.3% | -3.1% |
| Feb 19 | Clear Street | Upgrade | Hold → Buy | — | $11.24 | $11.86 | +5.5% | +4.1% | -5.0% | +1.5% | +5.8% | +1.8% |
| Feb 17 | William Blair | Upgrade | Market Perform → Outperform | — | $11.17 | $11.96 | +7.1% | +2.8% | -2.1% | +4.1% | -5.0% | +1.5% |
| Jan 29 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $11.69 | $14.80 | +26.6% | +13.9% | +0.2% | -2.1% | -2.7% | -3.5% |
| Jan 29 | Chardan Capital | Upgrade | Neutral → Buy | — | $11.69 | $14.80 | +26.6% | +13.9% | +0.2% | -2.1% | -2.7% | -3.5% |
| Jan 29 | Piper Sandler | Upgrade | Neutral → Overweight | — | $11.69 | $14.80 | +26.6% | +13.9% | +0.2% | -2.1% | -2.7% | -3.5% |
| Jan 28 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $10.74 | $11.42 | +6.3% | +8.8% | +13.9% | +0.2% | -2.1% | -2.7% |
| Jan 28 | Oppenheimer | Upgrade | Perform → Outperform | — | $10.74 | $11.42 | +6.3% | +8.8% | +13.9% | +0.2% | -2.1% | -2.7% |
| Nov 14 | Jones Trading | Downgrade | Buy → Hold | — | $6.50 | $5.77 | -11.2% | -6.6% | +1.3% | +1.1% | +3.1% | -6.6% |
| Nov 13 | William Blair | Downgrade | Outperform → Market Perform | — | $31.42 | $6.99 | -77.8% | -79.3% | -6.6% | +1.3% | +1.1% | +3.1% |
| Nov 13 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $31.42 | $6.99 | -77.8% | -79.3% | -6.6% | +1.3% | +1.1% | +3.1% |
| Nov 13 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $31.42 | $6.99 | -77.8% | -79.3% | -6.6% | +1.3% | +1.1% | +3.1% |
| Nov 13 | Chardan Capital | Downgrade | Buy → Neutral | — | $31.42 | $6.99 | -77.8% | -79.3% | -6.6% | +1.3% | +1.1% | +3.1% |
| Nov 13 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $31.42 | $6.99 | -77.8% | -79.3% | -6.6% | +1.3% | +1.1% | +3.1% |
| Aug 13 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $15.99 | $16.30 | +1.9% | +18.4% | +5.0% | +1.9% | -2.7% | -2.9% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $15.99 | $16.30 | +1.9% | +18.4% | +5.0% | +1.9% | -2.7% | -2.9% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.99 | $16.30 | +1.9% | +18.4% | +5.0% | +1.9% | -2.7% | -2.9% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.85 | $17.03 | +1.1% | -5.6% | +0.7% | -2.5% | -2.9% | +7.3% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.98 | $15.92 | -0.4% | -2.7% | -9.3% | +2.6% | +4.4% | +4.0% |
| May 13 | Chardan Capital | Maintains | Buy → Buy | — | $15.98 | $15.92 | -0.4% | -2.7% | -9.3% | +2.6% | +4.4% | +4.0% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $13.68 | -1.8% | +10.6% | +1.0% | +2.7% | -2.7% | -9.3% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.72 | $24.00 | +1.2% | -7.7% | +8.5% | +1.1% | -15.2% | -12.9% |
| Mar 19 | RBC Capital | Maintains | Outperform → Outperform | — | $24.17 | $24.40 | +1.0% | -1.9% | -7.7% | +8.5% | +1.1% | -15.2% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.62 | $51.37 | +1.5% | +3.3% | -0.6% | +2.4% | +3.3% | -5.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.14 | $65.98 | +1.3% | -15.6% | -9.7% | -4.3% | -2.0% | +0.0% |
| Oct 21 | RBC Capital | Maintains | Outperform → Outperform | — | $80.04 | $83.16 | +3.9% | -5.2% | -7.7% | -3.2% | +0.5% | +0.0% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $80.01 | $80.00 | -0.0% | +0.0% | -5.2% | -7.7% | -3.2% | +0.5% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $36.73 | $38.26 | +4.2% | +4.8% | -5.6% | -4.6% | +1.0% | -1.7% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.86 | $41.85 | +2.4% | -8.8% | -1.4% | +4.8% | -5.6% | -4.6% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.36 | $37.78 | +3.9% | +9.2% | +13.6% | -2.6% | -1.0% | -2.7% |
| Aug 14 | RBC Capital | Maintains | Outperform → Outperform | — | $36.36 | $37.78 | +3.9% | +9.2% | +13.6% | -2.6% | -1.0% | -2.7% |
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.60 | $54.01 | -1.1% | -7.0% | -1.2% | -4.2% | +1.6% | +1.5% |
| May 15 | BMO Capital | Maintains | Outperform → Outperform | — | $50.05 | $50.56 | +1.0% | +5.4% | -2.9% | +6.6% | -0.1% | -7.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.05 | $50.56 | +1.0% | +5.4% | -2.9% | +6.6% | -0.1% | -7.0% |
| Mar 28 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $88.53 | $89.86 | +1.5% | +1.7% | -0.3% | -7.9% | -5.7% | -8.4% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.53 | $89.86 | +1.5% | +1.7% | -0.3% | -7.9% | -5.7% | -8.4% |
| Mar 27 | RBC Capital | Maintains | Outperform → Outperform | — | $86.95 | $83.01 | -4.5% | +1.8% | +1.7% | -0.3% | -7.9% | -5.7% |
| Mar 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $86.95 | $83.01 | -4.5% | +1.8% | +1.7% | -0.3% | -7.9% | -5.7% |
| Mar 26 | BMO Capital | Maintains | Outperform → Outperform | — | $73.42 | $73.11 | -0.4% | +18.4% | +1.8% | +1.7% | -0.3% | -7.9% |
| Mar 12 | RBC Capital | Maintains | Outperform → Outperform | — | $56.15 | $56.54 | +0.7% | -1.4% | -3.0% | +10.2% | +3.9% | +0.6% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.02 | $40.85 | -0.4% | +0.2% | +3.4% | +1.2% | +20.8% | +0.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Dolan Oliver | Senior Vice President, Finance | Sell | 3,383 | $10.83 | $37K | 18,099 | +17.56% | — |
| Jun 16, 2026 | Cerio Jeffrey | General Counsel | Sell | 6,609 | $10.83 | $72K | 35,293 | +17.56% | — |
| Jun 16, 2026 | Vincent Loic A | Chief Scientific Officer | Sell | 3,418 | $10.83 | $37K | 18,297 | +17.56% | — |
| Jun 16, 2026 | Chappell Todd | Chief Operating Officer | Sell | 3,168 | $10.83 | $34K | 16,964 | +17.56% | — |
| May 29, 2026 | Aiyar Ram | President and CEO | Sell | 15,152 | $12.98 | $197K | 74,848 | +0.73% | +3.31% |
| May 28, 2026 | FORMELA JEAN FRANCOIS | — | Sell | 419 | $13.95 | $6K | 194,655 | -14.93% | -1.21% |
| May 28, 2026 | FORMELA JEAN FRANCOIS | — | Sell | 2,441 | $13.95 | $34K | 939,634 | -14.93% | -1.21% |
8-K · 8.01
!! High
Korro Bio, Inc. -- 8-K 8.01: Material Event / Announcement
May 19
8-K · 2.02
!! High
Korro Bio, Inc. -- 8-K 2.02: Earnings Results
Korro Bio reported Q1 2026 financial results, providing investors with updated information on the company's operational performance and financial condition for the quarter.
May 7
8-K
Unknown — 8-K Filing
Korro's RNA editing platform progress warrants investor attention as a differentiated approach to rare disease treatment; early clinical validation could drive significant upside if the platform proves commercially viable.
Mar 12
8-K · 1.01
! Medium
Korro Bio, Inc. -- 8-K 1.01: Equity Issuance
Korro Bio raised capital through a private placement led by Venrock Healthcare, securing funding from major institutional investors to advance its pipeline while issuing pre-funded warrants exercisable at nominal terms.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Atlas Venture Life Science Advisors, Llc | 1,137,149 | $13M | — | Mar 2026 |
| 2 | Adar1 Capital Management, Llc | 540,054 | $6M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 310,913 | $4M | New | Mar 2026 |
| 4 | Aqr Capital Management Llc | 267,755 | $3M | Added | Mar 2026 |
| 5 | Jane Street Group, Llc | 288,457 | $2M | New | Dec 2025 |
| 6 | 72 Investment Holdings, Llc | 276,831 | $2M | — | Dec 2025 |
| 7 | Two Sigma Investments, Lp | 165,472 | $2M | Added | Mar 2026 |
| 8 | Vanguard Portfolio Management Llc | 148,559 | $2M | New | Mar 2026 |
| 9 | Renaissance Technologies Llc | 136,227 | $2M | Added | Mar 2026 |
| 10 | Kalehua Capital Management Llc | 109,376 | $1M | New | Mar 2026 |
| 11 | Morgan Stanley | 139,456 | $1M | Reduced | Dec 2025 |
| 12 | Millennium Management | 63,606 | $720K | Reduced | Mar 2026 |
| 13 | Jpmorgan Chase & Co | 68,500 | $704K | Added | Mar 2026 |
| 14 | Northern Trust Corp | 57,702 | $653K | Added | Mar 2026 |
| 15 | Raymond James Financial Inc | 42,838 | $485K | Added | Mar 2026 |
| 16 | Acadian Asset Management Llc | 41,825 | $471K | Added | Mar 2026 |
| 17 | Fmr Llc | 38,900 | $440K | Added | Mar 2026 |
| 18 | Quantinno Capital Management Lp | 35,978 | $407K | Added | Mar 2026 |
| 19 | Marshall Wace, Llp | 34,343 | $389K | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 30,914 | $350K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$122.0M
Enterprise Value
$46.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.02x
P/B
2.37x
P/S
31.77x
P/FCF
-1.54x
EV/EBITDA
—
Shares Out
9.4M
Financials (TTM)
Revenue
$3.8M
Net Income
-$113.5M
EBITDA
-$78.1M
Free Cash Flow
-$79.1M
Op Cash Flow
-$78.6M
EPS Basic
$-12.48
EPS Diluted
$-11.68
EPS Forward
$-6.50
Gross Margin
73.2%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$113.5M
Total Liab.
$62.1M
Total Equity
$51.4M
Cash
$75.2M
LT Debt
$0
Book Value/Sh
$5.47
Debt/Equity
0.85x
Current Ratio
6.90
Quick Ratio
6.90
Returns & Growth
ROE
-228.0%
ROA
-103.3%
ROIC
-83.8%
Rev Growth YoY
+181.5%
EPS Growth YoY
-33.2%
Price Returns
2W
+21.0%
1M
-0.6%
3M
+10.6%
6M
+135.3%
12M
+17.4%
Technicals
52W High
$51.36
52W Low
$5.28
50d MA
$12.20
200d MA
$17.71
RSI (14)
47.50
ATR (14)
$1.10
Beta
2.43
Avg Volume
169K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.29
High
$30.00
Low
$10.00
Median
$22.00
Data updated apr 25, 2026 6:03pm
· Source: financialmodelingprep.com